The study and its comparison
A randomized trial included 50 participants. The study population was adults with active ulcerative colitis despite optimized mesalamine. Researchers compared curcumin 3 g daily or placebo alongside mesalamine, with follow-up over four weeks. [1]
Clinical remission occurred in fourteen of twenty-six curcumin recipients and none of twenty-four controls. The reported odds-ratio confidence interval was extremely wide, from 2.3 to 760. [1]
What the finding establishes
The trial tested induction of remission, not long-term maintenance or replacing mesalamine. Its size and short follow-up leave durability and uncommon harms unresolved. The striking point estimate should not obscure the imprecision or establish effectiveness for every turmeric preparation. Funding and complete conflicts were not established from the retrieved abstract. [1]
A hypothetical distinction
Imagine a large estimated effect has a very wide confidence interval. The direction can be promising while the magnitude remains uncertain.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.